Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.91 |
| ▸ | ARG2 | P78540 | 4/20 | 0.59 |
| ▸ | ARG1 | P05089 | 3/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 4/20 | 0.52 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL11904964 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8046798 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL3823204 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL27860697 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL27860695 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL296372 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL12470729 | 0.98 | GSR (0.87) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL318676 | 0.98 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1220993 | 0.98 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL10582149 | 0.98 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220243145-A1 | CAUSTIC CLEANING COMPOSITIONS | HSBC BANK MIDDLE EAST LIMITED (AE) | 2022-08-04 | — | — | US | claimed |
| WO-2022160034-A1 | CAUSTIC CLEANING-IN-PLACE COMPOSITIONS | FLUID ENERGY GROUP LTD (CA) | 2022-08-04 | — | — | WO | claimed |
| CN-113453548-A | Composition for maintaining viability of living and static biological material, method of manufacture and use thereof | 北哥罗夫投资公司 | 2021-09-28 | — | — | CN | claimed |
| EP-1558206-A1 | FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE | Australian Importers, Ltd (US) | 2005-08-03 | — | — | EP | claimed |
| WO-2004039348-A1 | FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE | AUSTRALIAN IMPORTERS, LTD. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040081681-A1 | Anhydrous formulations for percutaneous absorption | AUSTRALIAN IMPORTERS | 2004-04-29 | — | — | US | claimed |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | NOVO NORDISK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| WO-2022160034-A1 | CAUSTIC CLEANING-IN-PLACE COMPOSITIONS | FLUID ENERGY GROUP LTD (CA) | 2022-08-04 | — | — | WO | disclosed |
| US-20220243145-A1 | CAUSTIC CLEANING COMPOSITIONS | HSBC BANK MIDDLE EAST LIMITED (AE) | 2022-08-04 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| EP-3606560-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | Novo Nordisk A/S (DK) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185131-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | NOVO NORDISK A/S (DK) | 2018-10-11 | — | — | WO | disclosed |
| EP-2489653-B1 | METHOD FOR PRODUCING REDUCED COENZYME Q10 AND COMPOSITION COMPRISING SAME | KANEKA CORP (JP) | 2017-11-29 | — | — | EP | disclosed |
| US-7241456-B2 | Formulations for topical delivery of bioactive substances and methods for their use | AUSTRALIAN IMPORTERS LTD. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070071711-A1 | FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE | CELLMEDICS, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1558206-A1 | FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE | Australian Importers, Ltd (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004039348-A1 | FORMULATIONS FOR TOPICAL DELIVERY OF BIOACTIVE SUBSTANCES AND METHODS FOR THEIR USE | AUSTRALIAN IMPORTERS, LTD. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040081681-A1 | Anhydrous formulations for percutaneous absorption | AUSTRALIAN IMPORTERS | 2004-04-29 | — | — | US | disclosed |
| EP-0564154-B1 | A pharmaceutical formulation in the form of aqueous suspension | ROHTO PHARMA (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5334378-A | Suspension consists of complex of ion exchange resin and active ingredient, thickening agent consists of natural gums, cellulose derivatives and alginates, amino acid or salt stabilizer and water | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | IAPP, IDE, INSR | GSR 2836/4885ARG2 3147/4885ARG1 3410/4885 |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | IAPP, IDE, INSR | GSR 2836/4885ARG2 3147/4885ARG1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.